Inactive Instrument

eSense-Lab Ltd

Equities

ESE

AU000000ESE9

Biotechnology & Medical Research

Esense-Lab Ltd Reports Earnings Results for the Full Year Ended December 31, 2020

February 28, 2021 at 04:12 pm EST

eSense-Lab Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 3,000 compared to USD 13,000 a year ago. Operating income was USD 2.590 million compared to USD 1.720 million a year ago. Net loss was USD 4.041 million compared to USD 1.471 million a year ago. Basic loss per share from continuing operations was USD 0.012 compared to USD 0.008 a year ago.

Latest news about eSense-Lab Ltd

Esense-Lab Ltd Appoints Maayan Bar as External Directors	21-08-06	CI
ESense Lab : ESsense-lab Applies to Delist from Australian Bourse	21-06-25	MT
ESense lab : Widens 2020 Loss as Revenue Falls, Financial Expenses Jump	21-03-01	MT
Esense-Lab Ltd Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-28	CI
ESense-Lab Limited Provides Further Update on Research Agreement with Israeli MOH	21-02-16	CI
Esense lab : Secures Funds for Operational Expenditure, Working Capital	20-12-28	MT
ESense-Lab Ltd Announces Executive Changes	20-12-03	CI
ESense lab : Moves Toward Commercialization of Alcohol-Free Sanitizer	20-11-26	MT
ESense-Lab Ltd Provides Update on Research Agreement with Israeli Ministry of Health	20-11-26	CI
Esense-Lab Ltd Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-31	CI
ESense-Lab Ltd Signs A Research Agreement with the Israeli Ministry of Health to Commence A Joint Research Project	20-08-31	CI
Esense-Lab Ltd Announces Change in Registered Office Address	20-07-03	CI
ESense-Lab Ltd Announces Executive Changes, Effective July 6, 2020	20-07-03	CI
ESense-Lab Ltd Announces Board Changes	20-07-02	CI
ESense-Lab Ltd announced that it has received AUD 1.145 million in funding from Everblu Capital Pty. Ltd.	20-06-23	CI
ESense-Lab Limited Enters into Binding Joint Venture Agreement with Sassey Pty Ltd	20-06-17	CI
ESense-Lab Limited Signs JV Agreement with Anc Enterprises Ltd to Develop and Sell New Products	20-06-14	CI
ESense-Lab Ltd Announces Resignation of Amit Edri, Director	20-06-08	CI
ESense-Lab Ltd Enters into Letter of Intent with SeaLaria Ltd	20-05-27	CI
ESense-Lab Ltd announced that it expects to receive AUD 1.145 million in funding from Everblu Capital Pty. Ltd.	20-04-13	CI
ESense-Lab Limited Announces Resignation of Mike Edwards as Director	20-03-27	CI
ESense-Lab Ltd Announces Management Changes	20-03-05	CI
Esense-Lab Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-01	CI
ESense-Lab Limited Announces Executive Changes	20-01-28	CI
Esense Announces the Appointment of Dr James Ellingford as Director Effective from 13 January 2020	20-01-13	CI

Chart eSense-Lab Ltd

Duration

Period

More charts

Company Profile

Esense-Lab Ltd is an Israel-based pharmaceutical technology company. The Company re-engineers cannabis into a virtual plant, namely terpene, a naturally occurring chemical compounds that generate the flavor and fragrance synthesized by plants. Tarpene can be used both for medicinal purposes and for the production of cannabis-based consumer products. The Company mainly serves the legal cannabis and para-cannabis markets. It also serves the: e-liquid market; pharmaceuticals market, creating on demand customized profiles and personalized medicine, as well as rare plants market, providing sustainability to rare and sought after plants such as ginseng and saffron. Its cannabis terpenes address the cannabis edibles, e-liquids and energy drinks, as well as the essential oils markets.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research